Most new drugs are still too costly at launch, ICER says

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 20 Oct, 15:55 UTC

A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.

science

Sources

• T2Most new drugs are still too costly at launch, ICER saysBioPharma Dive / Healthcare Dive / MedTech Dive20 Oct, 15:55